Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03). - Kobayashi K; Masuda N; Mizuno T; Miura K; Tokuda Y; Yoshinami T; Kawaguchi H; Ohtani S; Saeki T; Toi M; Takeuchi M; Ito Y (Breast cancer research and treatment, 2023)